journal
https://read.qxmd.com/read/38733465/integrative-medicine-across-the-pediatric-cancer-care-trajectory-a-narrative-review
#1
REVIEW
Eran Ben-Arye, Noah Samuels, Georg Seifert, Orit Gressel, Raviv Peleg, Miek Jong
PURPOSE OF THE REVIEW: Children and adolescents with cancer, along with their parents and other informal caregivers, often report using complementary and alternative medicine (CAM) during active oncology and hemato-oncology treatment. Some adopt an "alternative" approach to conventional medical care, which often entails the use of these practices without the knowledge of the treating pediatrician. In contrast, many others search for consultation provided by a pediatric integrative oncology (IO) practitioner working with the conventional medical team...
May 11, 2024: Current Oncology Reports
https://read.qxmd.com/read/38713311/cdk4-6-inhibitors-the-devil-is-in-the-detail
#2
REVIEW
Tara Magge, Sneha Rajendran, Adam M Brufsky, Julia Foldi
PURPOSE OF REVIEW: Update on the most recent clinical evidence on CDK4/6 inhibitors (CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative breast cancer. RECENT FINDINGS: Over the past decade, CDK4/6i have become part of the standard of care treatment of patients with both metastatic and high-risk early HR + /HER2- breast cancers. The three available CDK4/6i (palbociclib, ribociclib and abemaciclib) have been extensively studied in combination with endocrine therapy (ET) in metastatic breast cancer (mBC) with consistent prolongation of progression free survival; however, ribociclib has emerged as the preferred first line agent in mBC given overall survival benefit over endocrine monotherapy...
May 7, 2024: Current Oncology Reports
https://read.qxmd.com/read/38709422/past-present-and-future-therapeutic-strategies-for-nf-1-associated-tumors
#3
REVIEW
Brian Na, Shilp R Shah, Harish N Vasudevan
PURPOSE OF REVIEW: Neurofibromatosis type 1 (NF-1) is a cancer predisposition syndrome caused by mutations in the NF1 tumor suppressor gene that encodes the neurofibromin protein, which functions as a negative regulator of Ras signaling. We review the past, current, and future state of therapeutic strategies for tumors associated with NF-1. RECENT FINDINGS: Therapeutic efforts for NF-1-associated tumors have centered around inhibiting Ras output, leading to the clinical success of downstream MEK inhibition for plexiform neurofibromas and low-grade gliomas...
May 6, 2024: Current Oncology Reports
https://read.qxmd.com/read/38683254/integrative-approaches-for-cancer-pain-management
#4
REVIEW
Reema Sabeeha Martini, Terrell Brown, Vinita Singh, Anna Woodbury
PURPOSE OF REVIEW: The goal of this review is to summarize updates to the broad array of complementary therapies available for cancer pain. This paper will serve as a reference for clinicians managing pain in cancer patients. RECENT FINDINGS: Patients are embracing integrative therapies in growing numbers; clinicians must be prepared to incorporate these therapies into patients' existing treatment regimens. This requires knowledge regarding risks, benefits, and potential interactions with existing cancer therapies...
April 29, 2024: Current Oncology Reports
https://read.qxmd.com/read/38676789/minimal-residual-disease-adapted-therapy-in-multiple-myeloma-current-evidence-and-opinions
#5
REVIEW
Mina Meseha, James Hoffman, Dickran Kazandjian, Ola Landgren, Benjamin Diamond
PURPOSE OF REVIEW: Multiple myeloma (MM) is a biologically heterogeneous malignancy with relatively uniform treatment paradigms. This review aims to assess the growing role of Minimal Residual Disease (MRD) assessment in facilitating response-adapted therapeutic decision making to individualize therapy in MM. RECENT FINDINGS: MRD has been repeatedly demonstrated to provide strong prognostic information, superseding traditional IMWG response criteria. The use of MRD to modulate therapy remains controversial...
April 27, 2024: Current Oncology Reports
https://read.qxmd.com/read/38668924/non-squamous-cancers-of-the-larynx
#6
REVIEW
H Bengu Cobanoglu, Erdal Rahman Koprucu
PURPOSE OF REVIEW: Although non-squamous tumors of the larynx are really rare, they may not always be viewed from the same perspective in the multidisciplinary treatment approach once the diagnosis is made. In this review, non-squamous tumors of the larynx and current approaches in treatment will be discussed. RECENT FINDINGS: When the studies and meta-analyses presented in the last 5 years are evaluated, it is seen that these tumors usually show non-specific symptoms...
April 26, 2024: Current Oncology Reports
https://read.qxmd.com/read/38652426/antibody-drug-conjugates-in-urological-cancers-a-review-of-the-current-landscape
#7
REVIEW
Aruni Ghose, Patricia Lapitan, Vedika Apte, Adheesh Ghosh, Abhinav Kandala, Sreejana Basu, Jo Parkes, Sayali D Shinde, Stergios Boussios, Anand Sharma, Prantik Das, Nikhil Vasdev, Sara E Rebuzzi, Yüksel Ürün, Ravindran Kanesvaran, Akash Maniam, Giuseppe L Banna
PURPOSE OF REVIEW: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care. RECENT FINDINGS: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer...
April 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38652425/navigating-breast-cancer-oligometastasis-and-oligoprogression-current-landscape-and-future-directions
#8
REVIEW
Stephanie M Yoon, Jose G Bazan
PURPOSE: We examine the potential for curative approaches among metastatic breast cancer (MBC) patients by exploring the recent literature on local ablative therapies like surgery and stereotactic body radiation therapy (SBRT) in patients with oligometastatic (OM) breast cancer. We also cover therapies for MBC patients with oligoprogressive (OP) disease. KEY FINDINGS: Surgery and SBRT have been studied for OM and OP breast cancer, mainly in retrospective or non-randomized trials...
April 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38652424/the-growing-role-of-digital-health-tools-in-the-care-of-patients-with-cancer-current-use-future-opportunities-and-barriers-to-effective-implementation
#9
REVIEW
Robert Haemmerle, Jonas Paludo, Tufia C Haddad, Joshua C Pritchett
PURPOSE OF REVIEW: This article aims to describe the ways in which digital health technologies are currently being used to improve the delivery of cancer care, highlight opportunities to expand their use, and discuss barriers to effective and equitable implementation. RECENT FINDINGS: The utilization of digital health tools and development of novel care delivery models that leverage such tools is expanding. Recent studies have shown feasibility and increased implementation in the setting of oncologic care...
April 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38647995/update-on-percutaneous-ablation-for-sarcoma
#10
REVIEW
Ahmad Parvinian, Scott M Thompson, John J Schmitz, Brian T Welch, Rebecca Hibbert, Daniel A Adamo, A Nicholas Kurup
PURPOSE OF REVIEW: To provide an update on the current state of percutaneous thermal ablation in the treatment of sarcoma. RECENT FINDINGS: Data continue to accrue in support of ablation for local control and palliation of specific sarcoma subtypes such as extra-abdominal desmoid fibromatosis and for broader indications such as the treatment of oligometastatic disease. The synergistic possibilities of various combination therapies such as cryoablation and immunotherapy represent intriguing areas of active investigation...
April 22, 2024: Current Oncology Reports
https://read.qxmd.com/read/38647994/current-status-of-partial-laryngeal-surgery-for-advanced-laryngeal-cancer-when-and-why
#11
REVIEW
Erika Crosetti, Marco Fantini, Ilaria Bertotto, Andy Bertolin, Giulia Arrigoni, Andrea Lorenzi, Giovanni Succo
PURPOSE OF REVIEW: This paper aims to evaluate the evolution and current status of partial laryngeal surgery in the treatment of advanced laryngeal cancer (LC). Specifically, recent progress in the selection of both patients and tumors, together with surgical and rehabilitation innovations, have contributed to balancing oncological control with the maintenance of quality of life in naïve and radiorecurrent patients. The main aspect is represented by the recognized role of open partial horizontal laryngectomies (OPHLs) in this new era of laryngeal cancer treatment...
April 22, 2024: Current Oncology Reports
https://read.qxmd.com/read/38639793/changing-the-perspective-on-fertility-preservation-for-women-with-metastatic-or-advanced-stage-cancer
#12
REVIEW
Mary Kathryn Abel, Ange Wang, Joseph M Letourneau, Michelle E Melisko, Marcelle I Cedars, Mitchell P Rosen
PURPOSE OF REVIEW: In this Perspective we share the personal story of a 33-year-old patient diagnosed with metastatic breast cancer and her journey through fertility preservation, surrogacy, and eventually motherhood, highlighting misconceptions about fertility preservation in this population. RECENT FINDINGS: There are nearly 1 million women under the age of 50 diagnosed and living with cancer in the USA. These patients are met with life-altering decisions, including those that may limit their reproductive ability...
April 19, 2024: Current Oncology Reports
https://read.qxmd.com/read/38625653/ablation-of-kidney-tumors-in-patients-with-substantial-kidney-impairment-current-status
#13
REVIEW
Toshihiro Iguchi, Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Hideo Gobara, Motoo Araki, Takao Hiraki
PURPOSE OF REVIEW: To review the current status of kidney tumor ablation in patients with substantial kidney impairment. RECENT FINDINGS: Few reports of kidney tumor ablation in such patients have recently been published. The reported prevalence of patients with stage 4 or 5 chronic kidney disease (CKD) among patients undergoing ablation is 2.0%-10%. In patients with stage 4 or 5 CKD, local tumor control rates were 88%-100%. The effect of ablation on CKD stage is unclear, and the observed deteriorations in kidney function are consistent with both the effect of cryoablation and the natural course of advanced CKD...
April 16, 2024: Current Oncology Reports
https://read.qxmd.com/read/38602581/management-of-oligometastatic-and-locally-recurrent-urothelial-carcinoma
#14
REVIEW
Michael A Liu, Jennifer W Li, Karie Runcie
PURPOSE OF REVIEW: To summarize and evaluate the literature on treatment approaches for oligometastatic and locally recurrent urothelial cancer. RECENT FINDINGS: There is no clear definition for oligometastatic urothelial cancers due to limited data. Studies focusing on oligometastatic and locally recurrent urothelial cancer have been primarily retrospective. Treatment options include local therapy with surgery or radiation, and generalized systemic therapy such as chemotherapy or immunotherapy...
April 11, 2024: Current Oncology Reports
https://read.qxmd.com/read/38598035/advances-in-radionuclide-therapies-for-patients-with-neuro-endocrine-tumors
#15
REVIEW
Denise S Hoogenkamp, Linda J de Wit-van der Veen, Daphne M V Huizing, Margot E T Tesselaar, Rachel S van Leeuwaarde, Marcel P M Stokkel, Marnix G E H Lam, Arthur J A T Braat
PURPOSE OF REVIEW: To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments. RECENT FINDINGS: Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i...
April 10, 2024: Current Oncology Reports
https://read.qxmd.com/read/38592590/current-systemic-therapy-in-men-with-metastatic-castration-sensitive-prostate-cancer
#16
REVIEW
Guillaume Grisay, Pernelle Lavaud, Karim Fizazi
PURPOSE OF REVIEW: This review aims to explore the evolving landscape of treatments available for metastatic castration-sensitive prostate cancer (mCSPC) patients. RECENT FINDINGS: In less than a decade, evidence was chronologically provided that (1) systemic treatment intensification with docetaxel improves outcomes, including survival, in men with mCSPC, (2) then that these outcomes are also improved when a second-generation androgen receptor pathway inhibitor (ARPI) is combined with androgen deprivation therapy (ADT), and (3) using a "triplet systemic therapy," which consists in the combination of ADT, an ARPI and docetaxel, further improves outcomes, including survival...
April 9, 2024: Current Oncology Reports
https://read.qxmd.com/read/38581470/patient-navigation-in-cancer-treatment-a-systematic-review
#17
REVIEW
Matthew Chen, Victoria S Wu, Derek Falk, Chesley Cheatham, Jennifer Cullen, Richard Hoehn
PURPOSE OF REVIEW: Patient navigation promotes access to timely treatment of chronic diseases by eliminating barriers to care. Patient navigation programs have been well-established in improving screening rates and diagnostic resolution. This systematic review aimed to characterize the multifaceted role of patient navigators within the realm of cancer treatment. RECENT FINDINGS: A comprehensive electronic literature review of PubMed and Embase databases was conducted to identify relevant studies investigating the role of patient navigators in cancer treatment from August 1, 2009 to March 27, 2023...
April 6, 2024: Current Oncology Reports
https://read.qxmd.com/read/38581469/radionuclide-theranostics-in-neuroendocrine-neoplasms-an-update
#18
REVIEW
Martina Di Franco, Lucia Zanoni, Emilia Fortunati, Stefano Fanti, Valentina Ambrosini
PURPOSE OF REVIEW: This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT). RECENT FINDINGS: Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET...
April 6, 2024: Current Oncology Reports
https://read.qxmd.com/read/38573440/current-trends-and-challenges-of-microbiome-research-in-prostate-cancer
#19
REVIEW
Shaun Trecarten, Bernard Fongang, Michael Liss
PURPOSE OF REVIEW: The role of the gut microbiome in prostate cancer is an emerging area of research interest. However, no single causative organism has yet been identified. The goal of this paper is to examine the role of the microbiome in prostate cancer and summarize the challenges relating to methodology in specimen collection, sequencing technology, and interpretation of results. RECENT FINDINGS: Significant heterogeneity still exists in methodology for stool sampling/storage, preservative options, DNA extraction, and sequencing database selection/in silico processing...
April 4, 2024: Current Oncology Reports
https://read.qxmd.com/read/38573439/perioperative-neurocognitive-function-in-glioma-surgery
#20
REVIEW
Kyle R Noll, Mariana Bradshaw, David Sheppard, Jeffrey S Wefel
PURPOSE OF REVIEW: This review provides a concise overview of the recent literature regarding preoperative and postoperative neurocognitive functioning (NCF) in patients with glioma. Brief discussion also covers contemporary intraoperative brain mapping work, with a focus on potential influence of mapping upon NCF outcomes following awake surgery. RECENT FINDINGS: Most patients with glioma exhibit preoperative NCF impairment, with severity varying by germ line and tumoral genetics, tumor grade, and lesion location, among other characteristics...
April 4, 2024: Current Oncology Reports
journal
journal
34702
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.